Michael Gelband’s Nuvation Bio NUVB Stock Holding History

Michael Gelband’s Portfolio NUVB Stock Details NUVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$380K	Sell	66,907 -96,780	-59%	-$473K	﹤0.01%	1303
2026 Q1	$702K	Buy	163,687 +103,379	+171%	+$576K	0.01%	1097
2025 Q4	$540K	Buy	60,308 +41,934	+228%	+$260K	﹤0.01%	1169
2025 Q3	$68K	Sell	18,374 -73,876	-80%	-$201K	﹤0.01%	1450
2025 Q2	$180K	Buy	+92,250	New	+$192K	﹤0.01%	1326
2025 Q1	–	Sell	-77,280	Closed	-$206K	–	1834
2024 Q4	$206K	Sell	77,280 -5,167	-6%	-$13.3K	﹤0.01%	1359
2024 Q3	$189K	Buy	+82,447	New	+$251K	﹤0.01%	1462
2023 Q1	–	Sell	-26,181	Closed	-$50K	–	2019
2022 Q4	$50K	Buy	+26,181	New	+$53K	﹤0.01%	1546
2021 Q2	–	Sell	-159,162	Closed	-$1.66M	–	2662
2021 Q1	$1.66M	Buy	+159,162	New	+$1.78M	0.02%	641

Other funds holding NUVB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

OFM

Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

DFO

Duquesne Family Office New York $5.21B AUM 87.01% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Michael Gelband's NUVB Position: Q2 2026 in Review

Michael Gelband reduced its Nuvation Bio (NUVB) stake by 59% in Q2 2026, selling an estimated $473K and leaving 66,907 shares worth $380K. The position accounts for ﹤0.01% of the portfolio, ranked #1303.

Michael Gelband first reported a position in NUVB in Q1 2021 and has held it in 9 quarters since. The position peaked at $1.66M in Q1 2021. 242 funds tracked by Wall St. Rank hold NUVB as of Q2 2026.

Michael Gelband held 66,907 shares of Nuvation Bio worth $380K as of Q2 2026.
Michael Gelband sold 96,780 Nuvation Bio shares in Q2 2026, an estimated $473K.
Nuvation Bio made up ﹤0.01% of Michael Gelband's portfolio in Q2 2026, its #1303 holding.
Michael Gelband first reported a position in Nuvation Bio in Q1 2021 and has held it in 9 quarters since.
Michael Gelband's Nuvation Bio position peaked at $1.66M in Q1 2021.
242 funds tracked by Wall St. Rank held Nuvation Bio as of Q2 2026.

Based on ExodusPoint Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.